Chronic depressive personality disorder also known as Dysthymia is a chronic form of depression. It is mild form of depression which last up to two years or more. This disorder is less severe in comparison to other forms of depression. Symptoms of chronic depressive personality disorder are loss of interest in daily activities, sadness, tiredness, trouble in concentrating and decision making, suicidal thoughts, and some others. Medication and psychotherapy are used for the management of chronic depressive personality disorder. Psychotherapy is preferred for children and adolescents instead of medication. But it also depend upon the severity of the chronic depressive personality disorder. Changing the lifestyle can also help in management of this disorder. Chronic depressive personality disorder treatment market is expected driven by increasing prevalence and increasing diagnosis. Chronic depressive personality disorder is a chronic disorder as suggested by the name which require a long term treatment measures. Requirement for long term treatment is also expected to drive the growth of this market. Government initiatives and awareness programs are also expected to fuel the growth of chronic depressive personality disorder treatment market. Effectiveness of psychotherapy alone and non-medicated treatment option can be restraint in the growth of medicated chronic depressive personality disorder treatment market. The global Chronic Depressive Personality Disorder Treatment market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Chronic Depressive Personality Disorder Treatment market based on company, product type, end user and key regions. This report studies the global market size of Chronic Depressive Personality Disorder Treatment in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Chronic Depressive Personality Disorder Treatment in these regions. This research report categorizes the global Chronic Depressive Personality Disorder Treatment market by top players/brands, region, type and end user. This report also studies the global Chronic Depressive Personality Disorder Treatment market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors. The following manufacturers are covered in this report, with sales, revenue, market share for each company: Eli Lilly Forest Laboratories GlaxoSmithKline Merck Sharp & Dohme Pfizer Allergan Novartis Market size by Product Selective Serotonin Reuptake Inhibitors Tricyclic Antidepressants Norepinephrine Reuptake Inhibitors Others Market size by End User Hospital Pharmacy Retail Pharmacy Online Pharmacy Market size by Region North America United States Canada Mexico Asia-Pacific China India Japan South Korea Australia Indonesia Singapore Malaysia Philippines Thailand Vietnam Europe Germany France UK Italy Spain Russia Central & South America Brazil Rest of Central & South America Middle East & Africa GCC Countries Turkey Egypt South Africa The study objectives of this report are: To study and analyze the global Chronic Depressive Personality Disorder Treatment market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025. To understand the structure of Chronic Depressive Personality Disorder Treatment market by identifying its various subsegments. To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks). Focuses on the key global Chronic Depressive Personality Disorder Treatment companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development. To project the value and sales volume of Chronic Depressive Personality Disorder Treatment submarkets, with respect to key regions. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market. In this study, the years considered to estimate the market size of Chronic Depressive Personality Disorder Treatment are as follows: History Year: 2014-2018 Base Year: 2018 Estimated Year: 2019 Forecast Year 2019 to 2025 This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Chronic Depressive Personality Disorder Treatment market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources. For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents 1 Study Coverage 1.1 Chronic Depressive Personality Disorder Treatment Product 1.2 Market Segments 1.3 Key Manufacturers Covered 1.4 Market by Type 1.4.1 Global Chronic Depressive Personality Disorder Treatment Market Size Growth Rate by Product 1.4.2 Selective Serotonin Reuptake Inhibitors 1.4.3 Tricyclic Antidepressants
